Dupont Capital Management Corp Purchases Shares of 62,571 Veracyte Inc (VCYT)

Share on StockTwits

Dupont Capital Management Corp bought a new position in shares of Veracyte Inc (NASDAQ:VCYT) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 62,571 shares of the biotechnology company’s stock, valued at approximately $787,000. Dupont Capital Management Corp owned 0.15% of Veracyte as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in Veracyte by 15.7% in the 3rd quarter. Wells Fargo & Company MN now owns 43,349 shares of the biotechnology company’s stock valued at $415,000 after purchasing an additional 5,885 shares during the period. Meeder Asset Management Inc. raised its holdings in shares of Veracyte by 79.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 16,178 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 7,182 shares in the last quarter. Teachers Advisors LLC grew its position in Veracyte by 21.1% during the 3rd quarter. Teachers Advisors LLC now owns 50,146 shares of the biotechnology company’s stock worth $479,000 after acquiring an additional 8,740 shares during the last quarter. Engineers Gate Manager LP grew its position in Veracyte by 38.4% during the 3rd quarter. Engineers Gate Manager LP now owns 34,214 shares of the biotechnology company’s stock worth $327,000 after acquiring an additional 9,495 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its position in shares of Veracyte by 3.5% in the 3rd quarter. Essex Investment Management Co. LLC now owns 315,286 shares of the biotechnology company’s stock worth $3,011,000 after buying an additional 10,531 shares during the last quarter. 88.69% of the stock is owned by institutional investors and hedge funds.

VCYT has been the subject of a number of recent research reports. BTIG Research lifted their price objective on Veracyte to $17.00 and gave the company a “buy” rating in a research note on Friday, January 4th. Janney Montgomery Scott lowered Veracyte from a “buy” rating to a “neutral” rating and set a $12.30 price target for the company. in a report on Thursday, November 29th. William Blair reaffirmed an “outperform” rating on shares of Veracyte in a research note on Tuesday, October 30th. BidaskClub upgraded Veracyte from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 22nd. Finally, Zacks Investment Research downgraded Veracyte from a “buy” rating to a “hold” rating in a research report on Saturday, January 19th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. Veracyte presently has a consensus rating of “Buy” and a consensus price target of $15.08.

In other Veracyte news, Chairman Bonnie H. Anderson sold 8,000 shares of the company’s stock in a transaction on Monday, December 10th. The shares were sold at an average price of $12.13, for a total value of $97,040.00. Following the completion of the transaction, the chairman now owns 59,236 shares in the company, valued at $718,532.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Bonnie H. Anderson sold 25,500 shares of the stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $15.29, for a total transaction of $389,895.00. Following the sale, the chairman now owns 94,041 shares of the company’s stock, valued at approximately $1,437,886.89. The disclosure for this sale can be found here. In the last three months, insiders sold 41,500 shares of company stock worth $632,295. 13.70% of the stock is owned by corporate insiders.

Shares of Veracyte stock opened at $18.30 on Thursday. The company has a market cap of $741.86 million, a PE ratio of -20.11 and a beta of 0.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 8.81 and a current ratio of 9.14. Veracyte Inc has a 1-year low of $5.23 and a 1-year high of $19.44.

TRADEMARK VIOLATION NOTICE: This article was originally reported by BBNS and is owned by of BBNS. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://baseballnewssource.com/2019/02/14/dupont-capital-management-corp-purchases-shares-of-62571-veracyte-inc-vcyt/3214923.html.

Veracyte Profile

Veracyte, Inc operates as a genomic diagnostics company in the United States. It uses genomic technology to resolve diagnostic uncertainty. The company offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Featured Article: What is a Stop Order?

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.